Page 1

May 12 , 2021 ADMA BIOLOGICS ADMA Biologics Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress and Accomplishments Achieved First Quarter 2021 Total Revenues of $ 16.0 Million , a 57 % Increase Over First Quarter 2020 Significantly Expanded Total Asset Value to $ 235.7 Million , Including $ 94.1 Million in Inventories Management to Host Conference Call and Webcast Today at 4:30 p.m. ET RAMSEY , N.J. and BOCA RATON , Fla . , May 12 , 2021 ( GLOBE NEWSWIRE ) -- ADMA Biologics , Inc. ( Nasdaq : ADMA ) ( " ADMA " or the " Company " ) , an end - to - end commercial biopharmaceutical company dedicated to manufacturing , marketing and developing specialty plasma - derived biologics , today reported financial results for its fiscal first quarter 2021 and provided an overview of recent progress and accomplishments . " ADMA has successfully transformed its business in the early months of 2021 and in doing so set the stage for what the Company expects to be a strong year of growth and achievements . We remain on track to deliver on several strategic and financial objectives over the near term , and visibility is improving on the Company's path to profitability , " said Adam Grossman , President and Chief Executive Officer of ADMA Biologics . " We achieved multiple milestones across business segments during the quarter , while at the same time delivered on operating commitments to shareholders , specifically , generating record quarterly revenues of $ 16.0 million , a 57 % increase over the same period last year . Also on the financial front , ADMA successfully narrowed both gross losses as well as net losses compared to the prior quarter , an encouraging trend the Company will strive to continue in the coming quarters and accelerate throughout 2022. " ADMA additionally grew its total asset value to a quarter - end balance of $ 235.7 million , up approximately 13 % compared to the year - end 2020 total asset value of $ 207.7 million . The growth in asset value notably includes approximately $ 94.1 million in inventories recorded at the Company's cost , which ADMA expects will support continued production ramp - up as well as quarter - over - quarter revenue growth throughout 2021 , and to ensure continuity of product supply into an increasingly supply - constrained immune globulin market . Mr. Grossman continued , " ADMA substantially strengthened its supply chain during the first quarter of 2021 , making significant progress towards its objective to establish end - to - end control of its production operations . Of note , the recent U.S. Food and Drug Administration ( " FDA " ) approval of the Company's Intravenous Immune Globulin ( “ IVIG ” ) production scale